Clinical Evidence
The data behind balloon-free catheterization
Peer-reviewed outcomes, head-to-head comparisons, and independent research — consolidated for value analysis committees, clinical review boards, and procurement teams.
At a Glance
Four things to know
0%
CAUTI Incidence
Zero catheter-associated UTIs in a prospective 50-patient clinical trial — vs. 10.5% with Foley catheters.1,2
~4.8 mL
Residual Urine
Near-complete bladder emptying. The Foley balloon obstructs the drainage eye, pooling residual urine that promotes bacterial colonization.1
57%
Foley Complication Rate
JAMA Internal Medicine: more than half of catheterized patients experience complications — and 5× more are noninfectious than infectious.2
0
Adoption Barriers
Same CPT code (51702), same insertion technique, same billing workflow. No new training, no prior authorization, no formulary friction.
The Problem
Catheter complications extend far beyond what hospitals measure
A landmark JAMA Internal Medicine study followed 2,076 catheterized patients across 4 U.S. hospitals. The findings redefine what "catheter harm" means. Read the full study ↗
The problem is bigger than infection
Hospital safety programs focus almost exclusively on CAUTI. But noninfectious complications — pain, bleeding, urgency, leaking, skin trauma — affected 5 in every 9 catheterized patients. These are complications associated with balloon-based catheterization that surveillance systems miss entirely.2
Activity and dignity costs are invisible
Among patients still catheterized at follow-up, 39.5% reported restrictions in daily living and 43.9% reported social activity limitations. The study's authors described the indwelling catheter as a "one-point restraint" — a burden current quality metrics do not capture.2
Growing malpractice exposure
A 50-year legal database review found that 48% of catheter-related malpractice claims involved traumatic insertion. Multiple lawsuits included spouse claims of loss of consortium. Balloon-based catheterization represents a growing liability exposure that a structural design change can address.10
Saint S, Trautner BW, Fowler KE, et al. JAMA Intern Med. 2018;178(8):1078-1085. doi:10.1001/jamainternmed.2018.2417
Downstream Impact
Catheter-associated UTI drives readmission and cost far beyond the index stay
An analysis of 2.5 million hospitalized UTI patients in the Premier Healthcare Database found that catheter-associated UTI carries the highest readmission burden of any UTI subtype — with skilled nursing facility patients at even greater risk.13
SNF patients face the highest readmission risk
Patients admitted from skilled nursing facilities with CA-UTI had the highest readmission rates of any UTI subgroup: 44% all-cause and 26% UTI-related within one year. These are the same patients most likely to have long-dwell indwelling catheters — and the population where balloon elimination has the greatest potential to reduce readmission cycles.13
CMS penalty exposure compounds with readmissions
Under the Hospital Readmissions Reduction Program, facilities face penalties up to 3% of Medicare reimbursement for excess readmissions. CMS separately penalizes bottom-quartile performers under the HAC Reduction Program. CA-UTI readmissions contribute to both penalty calculations — making catheter-associated infection a compounding financial liability.8
Judy BF, Kessler S, Gelman S, et al. Descriptive analysis of healthcare resource utilization and costs associated with treatment of urinary tract infections in United States hospitals. Am J Infect Control. 2022;50(2):190-198. doi:10.1016/j.ajic.2021.03.015
Clinical Proof
Prospective trial results
Prospective clinical trial data compared against published findings from JAMA Internal Medicine.
Peer-Reviewed · Published
The Lotus Catheter: A Non-Balloon Novel Urethral Catheter — A Prospective Study
50-patient prospective trial evaluating the Lotus catheter across multiple urological indications. Patients were assessed for CAUTI incidence, residual urine, pain, hematuria, and bladder spasms.
Read the full study
0%
CAUTI
~4.8 mL
Residual
0/10
Pain
0%
Hematuria
~2%
Spasms
~3 lbs
Pull-Out Force
| Metric | Lotus® Catheter | Foley Catheter |
|---|---|---|
| Deployment Time | ~4 seconds average deployment; removal in ~3 seconds (collapse wings) 1 | 10–30 seconds extra (estimated) just for balloon deflation before removal |
| Overall Complication Rate | 0% CAUTI, 0% hematuria, ~2% bladder spasms in prospective clinical trial 1 | 57% of patients reported at least one complication within 30 days — noninfectious complications were 5× more common than infectious 2 |
| CAUTI Incidence | 0% observed in 50-patient clinical trial 1 | 10.5% reported infectious complications including UTI 2 |
| Residual Urine | ~4.8 mL — near-complete emptying 1 | Balloon obstructs drainage eye, pooling urine that promotes bacterial growth 1 |
| Insertion Pain | 0/10 average; removal 2/10 1 | 54.5% reported pain or discomfort with catheter in place 2 |
| Hematuria / Removal Trauma | 0% on insertion or removal 1 | 30.9% reported pain, bleeding, or trauma at removal 2 |
| Bladder Spasms | ~2% — no balloon irritation to trigger spasms; designed to eliminate anticholinergic need (e.g. Ditropan) 1 | 24–35% — urgency or bladder spasms reported by 24.0% post-removal and 34.7% with catheter in place 2 |
| Weight on Trigone | 16g compressible — no sustained pressure on bladder's most sensitive area | 38–55g of non-compressible mass sitting directly on the trigone |
| Catheter Tip Length | ~0.5 cm — minimal bladder dome contact | 2.5–3 cm — presses into bladder dome under constant abdominal pressure; biopsy-confirmed inflammation within 6 hours 11 |
| Pull-Out Force | ~3 lbs (bench tested) — wings collapse safely; no urethral damage 1 | 20–50 lbs — non-compressible balloon; risk of serious urethral injury, stricture and incontinence |
| Self-Use Capable | Yes — patient home use capability | No — requires professional insertion |
| Functionality | 3-in-1 — Foley + Malecot + Straight in one device | Single function per catheter type |
Competitive Reality
Why coatings aren't enough
The largest randomized controlled trial of antimicrobial catheters — 7,102 patients across 24 hospitals — found no clinically significant reduction in symptomatic CAUTI.12 Coatings treat a symptom. Lotus addresses the cause.
The fundamental question
Coated catheters ask: how do we reduce bacteria on a balloon-based design?
Lotus asks: what if we remove the balloon entirely?
Coated Foley Catheter
Silver-alloy, nitrofurazone, antimicrobial variants
No significant benefit for symptomatic CAUTI. A 7,102-patient RCT found silver alloy catheters reduced symptomatic CAUTI by just 0.1% vs. standard catheters — a difference that was not statistically or clinically significant.12 A 2022 meta-analysis of 36,783 patients across 12 RCTs confirmed the finding (RR 0.87, p=0.06).14
Still pools residual urine above the balloon — the stagnant reservoir driving bacterial colonization remains1
Still places 38–55g on the trigone — biopsy-confirmed inflammation within 6 hours11
Still associated with removal trauma — 30.9% report pain, bleeding, or discomfort2
$5–$6+ premium per unit while preserving every structural limitation of the standard Foley12
Lotus Catheter
Balloon-free, wing-based retention
~4.8 mL mean residual — near-complete emptying designed to eliminate the bacterial reservoir1
16g compressible wings — no sustained trigone pressure, 0.5 cm tip1
0% hematuria — wings collapse at ~3 lbs with no urethral damage observed in clinical trial1
0% CAUTI observed (n=50) — addresses the infection mechanism, not just the symptom1
Priced to compete with standard Foleys — superior outcomes without a premium surcharge
What this means for catheter selection
The largest RCT to date found that antimicrobial coatings do not provide a clinically significant reduction in symptomatic CAUTI — yet these products command premium pricing based on that claim.12 Meanwhile, every structural limitation of the balloon remains: residual urine, tissue trauma, spasms, and painful removal. Lotus is the only FDA 510(k)-cleared catheter that removes the balloon entirely — addressing the structural cause rather than coating over it.
Reimbursement & Adoption
Same workflow. Same codes. Zero friction.
Lotus is reimbursed under established codes and inserted using identical clinical technique to the Foley — no new training, no new billing pathways, no formulary disruption.
Same billing code
Insertion billed under CPT 51702 — the same code used for Foley catheterization. No prior authorization, no new reimbursement pathways.
CPT 51702
Same insertion technique
Clinicians insert Lotus using the same procedure as a Foley. Wings deploy automatically once inside the bladder. No additional training or equipment required.
Cost-neutral to cost-positive
Priced to compete with standard Foleys. When factoring in CAUTI prevention, reduced CMS penalties, and elimination of anticholinergic prescriptions, Lotus is designed to lower total cost of care.
FDA 510(k) K191512
Class II Medical Device
Patent Protected through 2045
ISO 13485 Certified Manufacturing
500K+ Units Globally
Independent Research
What the literature says
Researchers have identified the balloon as a structural root cause of catheter-associated complications for decades — but until Lotus, no commercially viable alternative existed.
"The greatest opportunity for reducing the risk of catheter-associated urinary tract infection is to reduce the use of the catheter itself — and to fundamentally reconsider the design of the device."
Feneley RCL, Hopley IB, Wells PNT. Journal of Medical Engineering & Technology, 2015. Researchers estimated that achieving even 50% of a better catheter's potential would save approximately $18 billion annually in the U.S. 7
Biopsy-confirmed tissue damage within 6 hours
The Foley catheter tip (2.5–3 cm) pressing into the bladder dome produces acute and chronic inflammatory changes at the cellular level within 6 hours of insertion — demonstrated by biopsy-confirmed studies. Lotus reduces tip length to ~0.5 cm, designed to eliminate sustained dome contact. 11
CMS non-reimbursement as a design forcing function
Since 2008, CMS has refused to reimburse hospitals for CAUTI treatment costs — classifying them as a preventable "never event." This created a direct financial incentive to move beyond the Foley, yet the industry offered no viable structural alternative until Lotus. 8
Request the full clinical data package
Peer-reviewed study summaries, head-to-head comparison data, economic impact analysis, and product evaluation samples.
References
- Lockhart J, Boyle A, Kidd LC, et al. The Lotus Catheter: a Non-Balloon Novel Urethral Catheter — a Prospective Study. J Urol Ren Dis. 2017;125. View study →
- Saint S, Trautner BW, Fowler KE, et al. A Multicenter Study of Patient-Reported Infectious and Noninfectious Complications Associated With Indwelling Urethral Catheters. JAMA Intern Med. 2018;178(8):1078-1085. View study →
- Centers for Disease Control and Prevention. Catheter-Associated Urinary Tract Infections (CAUTI) — Background. cdc.gov →
- Tenke P, Mezei T, Bőde I, Köves B. Catheter-associated Urinary Tract Infections. Eur Urol Suppl. 2017;16(4):138–143. PMC9580547 →
- Centers for Disease Control and Prevention. NHSN CAUTI Protocol & Surveillance Manual. cdc.gov →
- Agency for Healthcare Research and Quality. CAUTI Toolkit — Implementation Guide Part 1. ahrq.gov →
- Feneley RCL, Hopley IB, Wells PNT. Urinary catheters: history, current status, adverse events and research agenda. J Med Eng Technol. 2015;39(8):459–470. View →
- CMS Hospital-Acquired Condition (HAC) Reduction Program. 42 CFR §412.172.
- Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, Prevention, and Treatment of CAUTI in Adults: 2009 International Clinical Practice Guidelines. Clin Infect Dis. 2010;50(5):625–663.
- Awad MA, Osterberg EC, Chang H, et al. Urethral catheters and medical malpractice: a legal database review from 1965 to 2015. Transl Androl Urol. 2016;5(5):762-773. View →
- Mohanty NK, Jha AK, Sharma SK, et al. Mitochondrial DNA induces Foley catheter related bladder inflammation via Toll-like receptor 9 activation. Sci Rep. 2018;8:6738. View →
- Pickard R, Lam T, MacLennan G, et al. Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial. Lancet. 2012;380(9857):1927-1935. View study →
- Judy BF, Kessler S, Gelman S, et al. Descriptive analysis of healthcare resource utilization and costs associated with treatment of urinary tract infections in United States hospitals. Am J Infect Control. 2022;50(2):190-198. View study →
- Barchitta M, Maugeri A, Favara G, et al. Catheter-Associated Urinary Infections and Consequences of Using Coated versus Non-Coated Urethral Catheters — Outcomes of a Systematic Review and Meta-Analysis of Randomized Trials. J Clin Med. 2022;11(15):4463. View study →
